Abstract
The authors report a 57-year-old patient with chronic inflammatory demyelinating polyneuropathy (CIDP) associated with diabetes mellitus (DM) who was treated successfully with rituximab. The B lymphocyte suppression using rituximab was followed 4 weeks later by neurological improvement and a stable disease course of over 10 months. We suggest that rituximab may be a treatment option in CIDP increasingly less responsive to intravenous immunoglobulin, particularly in patients with concurrent DM.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antirheumatic Agents / therapeutic use*
-
Diabetes Mellitus / drug therapy*
-
Diabetes Mellitus / physiopathology
-
Humans
-
Male
-
Middle Aged
-
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / complications
-
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / drug therapy*
-
Rituximab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antirheumatic Agents
-
Rituximab